Relationship between sleep and secretion of gonadotropin and ovarian hormones in women with normal cycles Sandrine Touzet, M.D., Muriel Rabilloud, M.D.,

Slides:

Advertisements

Similar presentations

Philip M. Sarrel, M. D. , Shannon D. Sullivan, M. D. , Ph. D

Advertisements

Antagonists in poor-responder patients

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Relationships between the luteinizing hormone surge and other characteristics of the menstrual cycle in normally ovulating women Ana Direito, M.D., Sébastien.

Age at menarche: a predictor of diminished ovarian function?

Male contraception Fertility and Sterility

Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.

Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation.

Follicular and endocrine response to anastrozole versus clomiphene citrate administered in follicular phase to normoovulatory women: a randomized comparison

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Leptin levels and luteinizing hormone pulsatility in normal cycling women and their relationship to daily changes in metabolic rate Rebecca M. Fenichel,

The normal variabilities of the menstrual cycle

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Rene Ecochard, M. D. , Ph. D. , Thomas Bouchard, M. D. , Rene Leiva, M

Urinary reproductive hormone level differences between African American and Caucasian women of reproductive age Susan R Reutman, Ph.D., Grace Kawas LeMasters,

Hypoestrogenic “inactive phases” at the start of the menstrual cycle: changes with age and reproductive stage, and relationship to follicular depletion

Ralf Dittrich, Ph. D. , Andreas Mueller, M. D. , Theodoros Maltaris, M

Failure of the GnRH antagonist ganirelix to block the positive feedback effect of exogenous estrogen in normal women Ioannis E. Messinis, M.D., Ph.D.,

Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm.

Effect of short-term hormone therapy on oxidative stress and endothelial function in African American and Caucasian postmenopausal women Raymond W Ke,

A comparison of blood spot vs

Potential diagnostic utility of intermittent administration of short-acting gonadotropin- releasing hormone agonist in gonadotropin deficiency Carrie.

Occurrence of postmenopausal-like acidic follicle-stimulating hormone (FSH) isoforms precedes the rise of FSH before menopause Chris M.G. Thomas, Ph.D.,

Christine L Cook, M. D. , Yong Siow, Ph. D. , Susan Taylor, B. A

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Leptin levels and luteinizing hormone pulsatility in normal cycling women and their relationship to daily changes in metabolic rate Rebecca M. Fenichel,

Prevalence of premature urinary luteinizing hormone surges in women with regular menstrual cycles and its effect on implantation of frozen-thawed embryos

Robert F. Casper, M.D. Fertility and Sterility

Success of intrauterine insemination in women aged 40–42 years

Conversion of high-response gonadotropin intrauterine insemination cycles to in vitro fertilization results in excellent ongoing pregnancy rates Amy.

René Ecochard, M. D. Ph. D. , Agnes Guillerm, M. D. , René Leiva, M. D

Susanna J. Park, M. D. , Laura T. Goldsmith, Ph. D. , Joan H

Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Effect of letrozole at 2. 5 mg or 5

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Rina Agrawal,

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Halvard Gjønnæss Fertility and Sterility

Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.

Concentrations of inhibins and activin in women undergoing stimulation with recombinant follicle-stimulating hormone for in vitro fertilization treatment

Mean versus individual hormonal profiles in the menstrual cycle

Hongxia Li, M. D. , Steven T Nakajima, M. D. , Jiangang Chen, M. D

MaryFran Sowers, Ph. D. , Daniel McConnell, Ph. D

Effectiveness of highly purified human menopausal gonadotropin vs

Regulation of assisted reproductive technologies in the United States

Stephanie A. Beall, M.D., Ph.D., Alan DeCherney, M.D.

Absence of corpus luteum rescue by chorionic gonadotropin in women immunized with a contraceptive vaccine Rahul Pal, Ph.D., Om Singh, Ph.D. Fertility.

Dana Rochester, M. D. , Akas Jain, M. D. , Alex J. Polotsky, M. D

Paolo Moghetti, M.D. Fertility and Sterility

Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.

A critique of the Women’s Health Initiative hormone therapy study

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization Efstratios M Kolibianakis, M.D., Kostas.

Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection.

Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin.

Female cancer survivors exposed to alkylating-agent chemotherapy have unique reproductive hormone profiles Lauren Johnson, M.D., M.S.C.E., Mary D. Sammel,

Inappropriate gonadotropin secretion in polycystic ovary syndrome

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Effectiveness of human menopausal gonadotropin versus recombinant follicle- stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive.

Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles David.

Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development

Defining the “sweet spot” for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect.

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

Use of recombinant human chorionic gonadotropin in ovulation induction

Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome Ernesto Bosch,

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Oocyte retrieval timing based on spontaneous luteinizing hormone surge during natural cycle in vitro fertilization treatment Daniel Bodri, M.D., M.Sc.,

Presentation transcript:

Relationship between sleep and secretion of gonadotropin and ovarian hormones in women with normal cycles Sandrine Touzet, M.D., Muriel Rabilloud, M.D., Ph.D., Hans Boehringer, Ph.D., Enriqueta Barranco, M.D., Ph.D., René Ecochard, M.D., Ph.D. Fertility and Sterility Volume 77, Issue 4, Pages 738-744 (April 2002) DOI: 10.1016/S0015-0282(01)03254-X

FIGURE 1 Mean levels of FSH, LH, estrone-3-glucuronide (E1-3-G), and pregnanediol-3-alpha-glucuronide (Pd-3α-G) in normally cycling women with short (<8 h, dotted line) or long (≥8 h, dashed line) sleep duration. Hormonal concentrations are log scaled. Touzet. Sleep and women’s reproductive hormones. Fertil Steril 2002. Fertility and Sterility 2002 77, 738-744DOI: (10.1016/S0015-0282(01)03254-X)